drugset / Trial / NCT07658976
Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy
Phase 3
Not yet recruiting
400 enrolled
HIV Prevention Trials Network
Gilead Sciences · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collabViiV Healthcare · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
Individual-Level Randomized Controlled Trial of an Integrated Strategy of HIV pre-exposure prophylaxis (PrEP) and sexually transmitted infection (STI) post-exposure prophylaxis (PEP) for Young Men
Timeline
- Start
- 2026-09-01
- Primary completion
- 2029-09-01
- Completion
- 2029-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxycycline | Small molecule | — | — |
| Background | CAB-LA | Unknown | — | — |
| Background | F/TAF | Unknown | — | — |
| Background | F/TDF | Unknown | — | — |